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a b s t r a c t 
The aim of this study was to describe the epidemiology and clinical impact of carbapenem-non- 
susceptible Pseudomonas aeruginosa (CNPA) in intensive care units (ICUs) of the national referral hospital 
of Indonesia. Adult patients admitted to ICUs were prospectively included. Pseudomonas aeruginosa were 
from clinical cultures and systematic screening. Environmental niches and healthcare workers (HCWs) 
were also screened. Susceptibility was determined phenotypically and the presence of carbapenemase 
genes was determined by PCR. Multiple loci variable-number tandem repeat analysis (MLVA) and multilo- 
cus sequence typing (MLST) were used for genotyping. Of the patients included in the study, 17/412 (4.1%) 
carried CNPA on admission and 34/395 (8.6%) became positive during their ICU stay. The acquisition rate 
was 18/10 0 0 patient-days at risk. Of 16 environmental isolates, 12 (75.0%) were CNPA. HCWs screened 
negative. Acquisition of CNPA was associated with longer ICU stay (adjusted hazard ratio = 1.89, 99% con- 
ﬁdence interval 1.12–3.13). Mortality was > 40% among patients with CNPA versus < 30% among those 
without CNPA ( P = 0.019). Moreover, 83/119 (69.7%) CNPA carried either bla VIM ( n = 36), bla IMP ( n = 23) or 
bla GES-5 ( n = 24). Four sequence types (STs) dominated (ST235, ST823, ST446 and ST357). Five major MLVA 
clusters were distinguished, two belonging to ST235 and the other three to ST823, ST446 and ST357. CNPA 
are introduced into these ICUs and some strains expand clonally among patients and the environment, 
creating endemic CNPA. VIM-, IMP- and GES-5 genes are prevalent. CNPA acquisition was associated with 
prolonged ICU stay and may affect ICU survival. 
© 2019 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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susceptible Pseudomonas aeruginosa in a large intensive care unit in 
https://doi.org/10.1016/j.ijantimicag.2019.08.003 seudomonal infections [1] . Non-susceptibility to carbapenem an-
ibiotics in P. aeruginosa is usually due to either a combination
f mechanisms, including β-lactamase production, increased eﬄux
ump activity and outer membrane modiﬁcations or to production
f a carbapenemase as a single potent resistance mechanism; VIM,
MP and GES-5 carbapenemases are most commonly found around
he world [2] . 
Little information exists on the epidemiology and impact of
NPA in Indonesia, the fourth most populous country in the world.nder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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s  In 2011, 21.9% of P. aeruginosa strains from the intensive care units
(ICUs) of the national referral hospital in Jakarta were carbapenem-
resistant, and four P. aeruginosa isolates contained the bla IMP gene
[3] . The aim of this study was to further delineate the clinical im-
pact and molecular epidemiology of CNPA in ICUs of this hospital. 
2. Materials and methods 
2.1. Study design 
A prospective observational study was performed from April–
October 2013 and from April–August 2014 in the 12-bed adult ICU
and 8-bed emergency room (ER)-ICU of Dr Cipto Mangunkusumo
General Hospital (Jakarta, Indonesia), with an average of 1010 and
415 admissions per year, respectively. Both ICUs are open-plan
wards [4] . 
Adult patients (age ≥18 years) admitted for > 48 h were eligible.
The ﬁrst screening cultures were taken on the day of ICU admis-
sion. Informed consent was obtained from the patients or their rel-
atives. Demographic and clinical characteristics were recorded on
admission. Systemic inﬂammatory response syndrome (SIRS) and
quick Sequential Organ Failure Assessment (qSOFA) score on ad-
mission were calculated. 
The primary outcome measure was acquisition of a CNPA be-
yond 48 h of ICU admission. Acquisition of CNPA was deﬁned as
ﬁrst detection of CNPA in a screening or clinical culture. Secondary
outcome measures were ICU length of stay (LoS) and in-ICU mor-
tality. 
Screening cultures were obtained from the throat and rectum
or stools on the day of admission, at the time of discharge from
the ICU, and weekly if the patient’s stay exceeded 7 days. Ster-
ile cotton-tipped swabs were used for sampling, which were pro-
cessed within 24 h. Additional samples were collected on clinical
indication. 
The environment was sampled twice in both ICUs (Supplemen-
tary Table S1). Screening of healthcare workers (HCWs) was per-
formed once by throat and rectal swabs. HCWs were deﬁned as
all personnel (doctors, nurses, cleaning staff, administration staff,
porters, nutritionist) working in the ICUs. 
2.2. Microbiological methods 
2.2.1. Isolation and identiﬁcation 
Swabs for screening were placed in 5 mL of trypticase soy broth
(TSB) with 2 mg/L cefotaxime and 50 mg/L vancomycin, were in-
cubated overnight and were subsequently subcultured on Mac-
Conkey agar, followed by identiﬁcation of suspected colonies us-
ing VITEK R ©2 (bioMérieux, Marcy-l’Étoile, France). Blood cultures
were collected in BACTEC R © (BD, Franklin Lakes, NJ, USA) bottles.
Other clinical specimens were inoculated onto blood and Mac-
Conkey agar plates and were processed as above. P. aeruginosa
strains were stored at –80 °C in TSB with 10% v/v glycerol. Their
identity was conﬁrmed at Erasmus MC (Rotterdam, the Nether-
lands) by mass spectrometry (MALDI Biotyper R ©; Bruker, Coventry,
UK). 
2.2.2. Antimicrobial susceptibility testing 
Susceptibility of screening isolates to carbapenems was deter-
mined by the Kirby–Bauer disk diffusion method using Mueller–
Hinton plates (BD). Susceptibility of the clinical isolates was
determined by VITEK R ©2. Carbapenem zone sizes and minimum in-
hibitory concentrations (MICs) were interpreted according to Eu-
ropean Committee on Antimicrobial Susceptibility Testing (EU-
CAST) 2013 breakpoints (meropenem, < 24 mm and MIC > 2 mg/L;
imipenem, < 20 mm and MIC > 4 mg/L). For detection of metallo-
β-lactamases (MBLs), the imipenem/doripenem combination diskPlease cite this article as: Y.R. Saharman, A.C. Pelegrin and A. Karuniaw
susceptible Pseudomonas aeruginosa in a large intensive care unit in 
https://doi.org/10.1016/j.ijantimicag.2019.08.003 est with ethylene diamine tetra-acetic acid (EDTA) was performed
5] . 
.2.3. DNA extraction and carbapenemase gene detection 
DNA was extracted using InstaGene TM Matrix (Bio-Rad Labora-
ories, Hercules, CA, USA). PCR for Ambler class B MBLs ( bla NDM ,
la VIM and bla IMP ) was carried out using a T30 0 0 Thermocycler
Biometra-Whatman, Germany) [6] . 
.2.4. Clonal relatedness 
Multiple loci variable-number tandem repeat analysis (MLVA)
nd in silico multilocus sequence typing (MLST) were used for typ-
ng (Supplementary Table S2) [7] . Brieﬂy, 2 μL of 100 ×diluted PCR
roduct was analysed on an ABI3130xl Genetic Analyzer (Thermo
isher Scientiﬁc, USA). Electropherograms were analysed using the
LVA plugin in BioNumerics R © v.7.6 (Applied Maths, Sint-Martens-
atem, Belgium). Typing data were analysed categorically. 
MLST sequence types (STs) as well as carbapenemase gene sub-
ypes were inferred from whole-genome sequencing data using
he MLST plugin and sequence extraction tool from BioNumerics R ©
.7.6. The classical 7-digit in silico MLST proﬁles were obtained
hrough BLAST using the PubMLST database hosted at https://
ubmlst.org . Sequencing was performed using a HiSeq 2500 instru-
ent (Illumina Inc., San Diego, CA, USA). 
.3. Statistical analysis 
IBM SPSS Statistics v.24.0 (IBM Corp., Armonk, NY) was used for
tatistical analysis. Patients admitted to the adult ICU were com-
ared with those admitted to the ER-ICU using χ2 test or Fisher’s
xact test and Mann–Whitney U -test as appropriate. One-way anal-
sis of variance (ANOVA) was used to compare patient character-
stics according to their P. aeruginosa status. Univariate and mul-
ivariate analyses were performed to establish risk factors associ-
ted with mortality using a multivariate logistic regression model
ith backward selection and inclusion of variables with a P -value
f < 0.1 in the univariate analysis. Cox proportional regression was
sed to analyse risk factors for LoS. The Kaplan–Meier method was
erformed to construct survival curves. A P -value of < 0.01 was
onsidered statistically signiﬁcant [8] . 
. Results 
.1. Patient characteristics and outcomes 
A total of 1211 patients were hospitalised in the ICUs (adult
CU, n = 863; ER-ICU, n = 348), of which 412 were included in this
tudy (adult ICU, n = 188; ER-ICU, n = 224). Most of the non-eligible
atients were excluded due to short LoS. There were no signiﬁ-
ant differences between patients in both ICUs, except that in the
dult ICU most patients had been referred from another ward and
ore patients had malignancies (Supplementary Table S3). There-
ore, data from the ICUs were analysed both separately and pooled.
Overall, 145/412 (35.2%) patients had at least one positive cul-
ure with P. aeruginosa , whereas the remaining 267 patients were
ree from P. aeruginosa on admission and during their ICU stay
 Table 1 ). A total of 83 patients (20.1%) already carried P. aerugi-
osa on the day of admission, of whom 66 carried a carbapenem-
usceptible P. aeruginosa (CSPA) and 17 carried a CNPA (Supple-
entary Fig. S1). Moreover, 34 patients acquired a CSPA and 34
atients acquired a CNPA. For the 51 patients with CNPA, 35 CNPA
ere obtained from screening, 6 from clinical cultures and 10 from
oth screening and clinical samples; there were no CNPA-positive
lood cultures. 
The dynamics of acquisition of P. aeruginosa in the ICUs is
hown in Fig. 1 A. Patients who acquired a CSPA had their ﬁrstati et al., Epidemiology and characterisation of carbapenem-non- 
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Table 1 
Patient characteristics and outcomes according to Pseudomonas aeruginosa status a . 
Characteristic Group 1 ( n = 267) Group 2 ( n = 60) Group 3 ( n = 17) Group 4 ( n = 34) Group 5 ( n = 34) P -value b 
Age (years) [median (IQR)] 46 (31–58) 44 (32–56) 43 (27–58) 49 (33–60) 47 (37–55) 0.895 
Sex [ n (%)] 0.530 
Male 137 (51.3) 27 (45.0) 11 (64.7) 20 (58.8) 19 (55.9) 
Female 130 (48.7) 33 (55.0) 6 (35.3) 14 (41.2) 15 (44.1) 
Underlying diseases [ n (%)] 
Cardiovascular 0.851 
Yes 16 (6.0) 4 (6.7) 1 (5.9) 3 (8.8) 1 (2.9) 
No 251 (94.0) 56 (93.3) 16 (94.1) 31 (91.2) 33 (97.1) 
Cerebrovascular 0.006 
Yes 12 (4.5) 6 (10.0) 0 (0) 4 (11.8) 7 (20.6) 
No 255 (95.5) 54 (90.0) 17 (100) 30 (88.2) 27 (79.4) 
Chronic kidney disease 0.130 
Yes 13 (4.9) 6 (10.0) 3 (17.6) 2 (5.9) 1 (2.9) 
No 254 (95.1) 54 (90.0) 14 (82.4) 32 (94.1) 33 (97.1) 
Diabetes mellitus 0.262 
Yes 24 (9.0) 1 (1.7) 1 (5.9) 3 (8.8) 4 (11.8) 
No 243 (91.0) 59 (98.3) 16 (94.1) 31 (91.2) 30 (88.2) 
Malignancy 0.379 
Yes 74 (27.7) 17 (28.3) 6 (35.3) 14 (41.2) 7 (20.6) 
No 193 (72.3) 43 (71.7) 11 (64.7) 20 (58.8) 27 (79.4) 
Indication for ICU admission [ n (%)] 0.005 
Medical 78 (29.2) 22 (36.7) 9 (52.9) 11 (32.4) 20 (58.8) 
Surgical 189 (70.8) 38 (63.3) 8 (47.1) 23 (67.6) 14 (41.2) 
Referral from [ n (%)] 0.120 
Other ward in this hospital 141 (52.8) 26 (43.3) 10 (58.8) 25 (73.5) 20 (58.8) 
Other hospital 46 (17.2) 15 (25.0) 3 (17.6) 4 (11.8) 9 (26.5) 
Directly from ER 80 (30.0) 19 (31.7) 4 (23.5) 5 (14.7) 5 (14.3) 
Antibiotic exposure pre-ICU admission [ n (%)] 
Any antibiotic 189 (70.8) 52 (86.7) 12 (70.6) 28 (82.4) 30 (88.2) 0.020 
Carbapenem 41 (15.4) 9 (15.0) 8 (47.1) 4 (11.8) 17 (50.0) 0.000 ∗∗
SIRS score [ n (%)] 0.530 
≥2 240 (89.9) 56 (93.3) 17 (100) 31 (91.2) 33 (97.1) 
< 2 27 (10.1) 4 (6.7) 0 (0) 3 (8.8) 1 (2.9) 
qSOFA score [ n (%)] 0.014 
≥2 205 (76.8) 51 (85.0) 17 (100) 29 (85.3) 32 (94.1) 
< 2 62 (23.2) 9 (15.0) 0 (0) 5 (14.7) 2 (5.9) 
Procedures during ICU admission 
Mechanical ventilation (%) 233 (87.3) 55 (91.7) 17 (100) 33 (97.1) 33 (97.1) 0.126 
Mechanical ventilation duration 0.000 ∗∗
≥5 days 99 (37.1) 28 (46.7) 13 (76.5) 17 (50.0) 25 (73.5) 
< 5 days 168 (62.9) 32 (53.3) 4 (23.5) 17 (50.0) 9 (26.5) 
Central venous catheter (%) 230 (86.1) 52 (86.7) 17 (100) 31 (91.2) 33 (97.1) 0.196 
Central venous catheter duration 
≥5 days 125 (46.8) 33 (55.0) 13 (76.5) 23 (67.6) 29 (85.3) 
< 5 days 142 (53.2) 27 (45.0) 4 (23.5) 11 (32.4) 5 (14.7) 
Urinary catheter [ n (%)] 267 (100) 60 (100) 17 (100) 34 (100) 34 (100) N/A 
Urinary catheter duration 0.001 
≥5 days 148 (55.4) 35 (58.3) 13 (76.5) 25 (73.5) 30 (88.2) 
< 5 days 119 (44.6) 25 (41.7) 4 (23.5) 9 (26.5) 4 (11.8) 
Antibiotic therapy during ICU admission [ n (%)] 
Any antibiotic 263 (98.5) 59 (98.3) 16 (94.1) 34 (100) 34 (100) 0.460 
Carbapenem 114 (42.7) 31 (51.7) 14 (82.4) 12 (35.3) 28 (82.4) 0.000 ∗∗
Outcomes 
ICU LoS (days) [median (IQR)] 4 (3–7) 5 (3–10) 6 (4–12) 7 (3–12) 16 (6–27) 0.000 ∗∗
In-ICU mortality [ n (%)] 74 (27.7) 18 (30.0) 8 (47.1) 5 (14.7) 14 (41.2) 0.064 
CNPA, carbapenem-non-susceptible P. aeruginosa ; CSPA, carbapenem-susceptible P. aeruginosa ; ER, emergency room; ICU, intensive care unit; IQR, interquartile range; LoS, 
length of stay; N/A, not applicable; qSOFA, quick Sepsis-related Organ Failure Assessment; SIRS, Systemic Inﬂammatory Response Syndrome. 
a Group 1, no P. aeruginosa on admission and negative for P. aeruginosa during ICU admission; group 2, CSPA on admission, no CNPA acquisition during ICU admission; 
group 3, CNPA on admission, considered as positive during ICU admission (regardless of results of follow-up cultures); group 4, no P. aeruginosa on admission, acquisition of 
CSPA during ICU admission; and group 5, either no P. aeruginosa or CSPA on admission, acquisition of CNPA during ICU admission. 
b Signiﬁcance was calculated using one-way analysis of variance (ANOVA), Pearson’s χ 2 test and Fisher’s exact test. A P -value of < 0.01 was considered statistically signiﬁ- 
cant. 
∗∗ P < 0.001. 
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 P = 0.065). The acquisition rate of CSPA was 19/10 0 0 patient-days
t risk (adult ICU, 22; ER-ICU, 14) compared with 18/10 0 0 patient-
ays at risk for CNPA (adult ICU, 15; ER-ICU, 21). 
Patients who acquired CNPA had a signiﬁcantly longer LoS
median [interquartile range (IQR)] LoS, 15 [6–26] days; adjusted
azard ratio (aHR) = 1.89, 99% conﬁdence interval (CI) 1.12–3.13;
 = 0.002) (Supplementary Table S4; Fig. 1 B) compared with the
ther groups of patients, of whom ≥80% were discharged from thePlease cite this article as: Y.R. Saharman, A.C. Pelegrin and A. Karuniaw
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ere always free from P. aeruginosa , patients who already carried
. aeruginosa (either CSPA or CNPA) at the time of ICU admission,
nd patients who became positive for CSPA during their ICU stay. 
A longer LoS was independently associated with mechanical
entilation ≥5 days (median [IQR] LoS, 10 [7–15] days; aHR = 3.09,
9% CI 1.98–4.83; P < 0.001) (Supplementary Table S4) and use
f a urinary catheter ≥5 days (median [IQR] LoS, 8 [5–12] days;
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Fig. 1. Acquisition of carbapenem-susceptible Pseudomonas aeruginosa (CSPA) and 
carbapenem-non-susceptible P. aeruginosa (CNPA) and its effect on intensive care 
unit (ICU) stay and survival. (A) Acquisition of CSPA (orange) and CNPA (blue) ( P - 
value by independent Mann–Whitney U -test). (B) Length of ICU stay by P. aerug- 
inosa status: patients who were always P. aeruginosa negative (blue); patients al- 
ready positive for CSPA on admission (green); patients already positive for CNPA on 
admission (yellow); patients who acquired CSPA during their ICU stay (red); and 
patients who acquired CNPA during their ICU stay (black) ( P -value by Cox regres- 
sion). (C) Survival of patients acquiring a CSPA (blue) compared with a CNPA (red) 
during their ICU stay ( P -value by binary regression). 
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https://doi.org/10.1016/j.ijantimicag.2019.08.003 Acquisition of P. aeruginosa was not associated with in-ICU mor-
ality: 27.7% (74/267) of patients who remained free of P. aerugi-
osa died versus 14.7% (5/34) and 41.2% (14/34) of patients who
cquired a CSPA or CNPA, respectively [Supplementary Table S5;
djusted odds ratio (aOR) = 0.41, 99% CI 0.10–1.71; P = 0.109; and
OR = 1.08, 99% CI 0.34–3.46; P = 0.867]. The group of patients who
cquired CSPA had the lowest mortality rate, and the probabil-
ty of ICU survival was higher for patients who acquired a CSPA
ompared with patients who acquired CNPA (aHR = 4.06, 99% CI
.87–18.88; P = 0.019) ( Fig. 1 C). Likewise, the ICU mortality among
ll patients with CNPA was 22/51 (43.1%) versus 97/361 (26.9%)
mong patients without CNPA ( P = 0.016). The admission SIRS and
SOFA scores of patients with or without P. aeruginosa acquisition
id not differ, indicating that signiﬁcant differences in the risk of
ying were not present at the time of ICU admission but emerged
ater during their ICU stay (Supplementary Table S5). In multivari-
te comparison, patients who acquired a CNPA during their ICU
tay were more likely to have had prior exposure to antibiotics,
specially carbapenems (aOR = 2.67, 99% CI 0.94–7.62; P = 0.015). 
.2. Phenotypic and molecular characterisation of 
arbapenem-non-susceptible Pseudomonas aeruginosa 
Overall, 107/281 (38.1%) isolates from 51/145 patients were
ound to be non-susceptible to carbapenems. Moreover, 12/16
75.0%) P. aeruginosa isolates from the environment were CNPA
Supplementary Table S6). None of 25 isolates from HCWs were
NPA. Thus, 119 CNPA were subjected to further analyses. Pheno-
ypic testing showed that 68/119 (57.1%) isolates produced a MBL.
CR demonstrated the presence of bla VIM in 36 and bla IMP in 23,
ncluding isolates from patients and the environment. None of the
19 isolates were positive for bla NDM . The presence of non-MBL
la GES-5 was detected in 24 isolates. 
.3. Clonal relatedness 
MLST revealed four major clusters (ST235, ST823, ST446 and
T357) as well as several new sequence types. By MLVA, ﬁve ma-
or clusters were distinguished, two belonging to ST235 and the
thers corresponding to ST823, ST446 and ST357 ( Fig. 2 A). These
our major genetic clusters included 97/107 (90.7%) CNPA from pa-
ients (ICU-imported and ICU-acquired) as well as 11/12 (91.7%) en-
ironmental isolates ( Fig. 2 B). Most isolates belonged to ST235 (10
mported, 32 acquired patient isolates and 4 environmental iso-
ates), of which 22 isolates harboured bla IMP , 24 isolates harboured
la GES-5 but no isolates contained bla VIM . All ST823 isolates har-
oured bla VIM (Supplementary Tables S6 and S7). 
. Discussion 
Reports describing the emergence of P. aeruginosa isolates har-
ouring carbapenemase genes come from different parts of the
orld, including Southeast Asia [9] . In the current study, it was
ound that 12.4% of patients who stayed in our ICUs for > 2 days
arried CNPA and 4.1% of patients were already colonised at ICU
dmission. Patients may become colonised elsewhere in the same
ospital or in another hospital from which they are referred, or
hey may come with such a strain directly from the community,
ossibly having acquired the strain during previous healthcare con-
act or indirectly from exposure to relatives carrying such strains
r unknown environmental niches. 
Hence, screening cultures are indispensable for early detection
nd infection control. This will also guide rational antibiotic use
ince it has been shown that colonisation with CNPA is a risk factor
or infection [10] . ati et al., Epidemiology and characterisation of carbapenem-non- 
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Fig. 2. Minimum spanning tree analysis of carbapenem-non-susceptible Pseudomonas aeruginosa (CNPA) isolates based on multiple loci variable-number tandem repeat 
analysis (MLVA). Grey shading in each panel indicates MLVA complexes. (A) Five most prevalent MLVA clusters corresponded to ST235 (green), ST823 (red), ST446 (purple), 
ST357 (yellow) and ST244 (light blue) as determined by multilocus sequence typing (MLST). Minor clones are indicated by other colours. (B) Red segments indicate P. 
aeruginosa isolates that were imported into the intensive care unit (ICU) by patients, green segments indicate those that were acquired in the ICU by patients, and purple 
segments indicate isolates from the ICU environment. (C) Coloured segments indicate the carbapenemase genes VIM-2 (green), GES-5 (red), IMP-7 (light blue), IMP-1 (yellow) 
and IMP-43 (purple). Colourless segments represent isolates without carbapenemase genes. 
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a  The current data show that patient acquisition of CNPA during
CU care is associated with prolonged ICU stay. Acquisition of CSPA
r CNPA was statistically not associated with mortality compared
ith patients free of P. aeruginosa . However, the observed mortal-
ty rate was much higher among patients with CNPA versus those
ithout. A study in Taiwan in 2016 also did not ﬁnd carbapenem
esistance to be associated with mortality [11] , whereas another
tudy revealed a relationship between CNPA carriage and mortality
12] . 
Among the 107 CNPA, bla VIM , bla IMP and bla GES-5 were the
ost prevalent carbapenemase genes. These genes are widely dis-
ributed in the world. The ﬁrst MBL found in P. aeruginosa was
MP-1, identiﬁed in Japan in 1988. VIM was ﬁrst identiﬁed in
taly in 1997, but reached Southeast Asia [ 2 , 9 ]. GES-5-producing P.
eruginosa was ﬁrst detected in China in 2004 and has been iso-
ated globally since [13 , 14] . 
In a recent review it was shown that use of carbapenems and
edical devices are the leading risk factors for carriage of CNPA
15] . The authors also identiﬁed environmental sources of CNPA,
ith sinks being the most frequently reported reservoirs [16] . More
ecent reports of outbreaks of CNPA also demonstrate an associa-
ion with environmental contamination [17–19] . This phenomenon
as also observed in our setting. The four environmental bla IMP -
ositive ST235 CNPA were all cultured from wet sources in the
ommon cleaning room. In this room, located adjacent to the adult
CU, all reusable items are manually cleaned and stored. These
ypes of ‘wet’ rooms may serve as a persistent source and routePlease cite this article as: Y.R. Saharman, A.C. Pelegrin and A. Karuniaw
susceptible Pseudomonas aeruginosa in a large intensive care unit in 
https://doi.org/10.1016/j.ijantimicag.2019.08.003 f transmission for resistant bacteria and should be targeted by in-
ection control. 
MLST revealed four major clusters (ST235, ST823, ST446 and
T357) and several new clones. ST235 is the most prevalent of the
o-called ‘international’ clones that are associated with poor clini-
al outcomes [20] . The Indonesian offspring of this clone, identiﬁed
n this study, always harboured bla IMP or bla GES-5 , but not bla VIM .
ll ST823 isolates consistently harboured only bla VIM , and only
la IMP was found in ST357, but no genes in ST446. Three dominant
lusters included isolates from the ICU environment (ST235, ST823
nd ST446). This epidemiological information should be used when
esigning interventions to reduce the acquisition of CNPA in ICUs
n Indonesia and similar settings elsewhere. 
This study has limitations. First, it was a single-centre study,
herefore the data are not representative for the whole country.
econd, we were unable to evaluate the effect of several other pos-
ible confounders of CNPA acquisition, including long-term kidney
ialysis, use of inotropes, surgery and previous hospital admission.
. Conclusion 
This large prospective study describes the epidemiology and
linical impact of CNPA in ICUs in Indonesia. Acquisition of CNPA
n ICUs was independently associated with prolonged LoS and pos-
ibly survival. ST235 was the dominant clone, as were IMP, VIM
nd GES carbapenemases. Controlling CNPA requires admissionati et al., Epidemiology and characterisation of carbapenem-non- 
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 screening of patients and identifying and containing reservoirs
within the ICU environment. 
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